Paolo A. Ascierto: Microbiota and immunotherapy – the new frontiers for the treatment of melanoma
Paolo A. Ascierto, Director of Department Melanoma at Cancer Immunotherapy and Development Therapeutics, shared a post by INNLIFES, adding:
“Immunotherapy has revolutionized the natural history of melanoma.
In this interview with INNLIFES, I discussed the evolution of immunotherapy, the role of the microbiota, new therapeutic perspectives, and the challenges ahead in providing patients with increasingly effective solutions in the fight against this type of cancer. Research never stops!
Read the full interview here.”
Quoting INNLIFES’s post below:
“Microbiota and immunotherapy: the new frontiers for the treatment of melanoma
The IRCCS is involved in several clinical trials on immunotherapy for melanoma.
Prof. Paolo A. Ascierto takes stock of new therapeutic strategies based on a mix of MB097 bacteria, mRNA vaccines and Tils cell therapy, to improve the effectiveness of immunotherapy treatments.
The Pascale Institute in Naples is engaged in several clinical trials on immunotherapy for melanoma. Prof. Paolo Ascierto reviews new therapeutic strategies based on MB097 bacteria mix, mRNA vaccines, and Tils cell therapy to improve the efficacy of immunotherapy treatments”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023